Vorinostat

DALLAS — Multiple factors predicted improved survival among patients with head and neck or salivary gland cancers treated with pembrolizumab plus vorinostat, according to prospective study results.

The combination of pembrolizumab and vorinostat demonstrated efficacy among patients with relapsed or refractory Hodgkin lymphoma, according to phase 2 study results presented at ASH Annual Meeting and Exposition.

The combination of bortezomib and vorinostat appeared safe and showed moderate activity among patients with diffuse large B-cell lymphoma and mantle cell lymphoma, according to a nonrandomized multicenter phase 2 trial.